Chimeric Antibody 14D5 Protects Mice against the Far-Eastern, Siberian, and European Tick-borne Encephalitis Virus
Authors:
- Andrey L. MatveevAMAndrey L. Matveev
- Irina V. KozlovaIKIrina V. Kozlova
- Elena K. DoroshchenkoEDElena K. Doroshchenko
- Oleg V. StroninOSOleg V. Stronin
- Oksana V. LisakOLOksana V. Lisak
- Olga V. SuntsovaOSOlga V. Suntsova
- Yulia S. SavinovaYSYulia S. Savinova
- Lyudmila A. EmelyanovaLELyudmila A. Emelyanova
- Ivan K. BaykovIBIvan K. Baykov
- Nina V. TikunovaNTNina V. Tikunova
Open Access
- 4 April 2019
- journal article
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 4 (1) , 143-149
Abstract
Tick-borne encephalitis virus (TBEV), belonging to the Flaviviridae family, is the most significant pathogen transmitted by Ixodes ticks and causing one of the most severe human neuroinfections. In Russia, serum immunoglobulin produced from the donor blood is currently used for post-exposure prophylactic and therapy of tick-borne encephalitis virus. However, it is known that preparations obtained from donated blood have certain disadvantages, and therefore development of novel preparations for post exposure prophylaxis and therapy of tick-borne encephalitis is required. To develop an alternative preparation, which does not include donor blood, a chimeric antibody ch14D5 against glycoprotein E of TBEV was constructed.This study was aimed to investigate protective efficacy of the chimeric antibody ch14D5 against the Far-Eastern, Siberian, and European subtypes of TBEV in in vivo experiments.A peripheral mouse model of tick-borne encephalitis was used in this study: the chimeric antibody ch14D5 was administrated intravenously in mice one day after their intraperitoneal infection with TBEV strains Sofjin, Vasilchenko, and Absettarov. Anti-TBEV serum immunoglobulin was used as a control preparation, which was administered in the same way. Protective efficacy of the chimeric antibodies 14D5 was assessed using the log-rank test. In the study, the presence or absence of antibody-dependent enhancement of infection (ADE) was examined when mice, infected with different subtypes of the TBEV, got the antibody ch14d5.Obtained results demonstrated high efficacy of the ch14D5 antibody in post-exposure prophylaxis of the disease in mice infected with any of the used TBEV strains, as well as the absence of ADE.It was shown that protective efficacy of antibody ch14D5 is higher than that of the anti-TBEV serum immunoglobulin, and antibody ch14D5 could be used for development of a therapeutic preparation for post-exposure prophylaxis.Keywords
This publication has 14 references indexed in Scilit:
- CHARACTERISTICS OF THE BAIKAL SUBTYPE OF TICK-BORNE ENCEPHALITIS VIRUS CIRCULATING IN EASTERN SIBERIAActa Biomedica Scientifica, 2018
- A novel mechanism of antibody-mediated enhancement of flavivirus infectionPLOS Pathogens, 2017
- Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunityScience, 2017
- Biologic Evidence Required for Zika Disease Enhancement by Dengue AntibodiesEmerging Infectious Diseases, 2017
- Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virusVavilov Journal of Genetics and Breeding, 2017
- A protective chimeric antibody to tick-borne encephalitis virusVaccine, 2014
- Vaccines against tick-borne encephalitis: WHO position paper – RecommendationsVaccine, 2011
- Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesisVirus Research, 2005
- Epitope analysis of tick-borne encephalitis (TBE) complex viruses using monoclonal antibodies to envelope glycoprotein of TBE virus (persulcatus subtype)Virus Research, 1993
- A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12American Journal of Epidemiology, 1938